

BIOCON GROUP

FACT SHEET

December 2010

YTD FY 2011 vs. YTD FY 2010

Q3 FY 2011 vs. Q3 FY 2010

BIOCON LIMITED (CONSOLIDATED)		
BALANCE SHEET		<i>(Rs. Crores)</i>
	December-10	March-10
<u>SOURCES OF FUNDS</u>		
Share Capital	100	100
Reserves & Surplus	1,936	1,658
Total Shareholder's Funds	2,036	1,758
Minority interest	37	34
Deferred Tax Liability	48	51
Secured Loans	291	332
Unsecured Loans	85	182
Total Loan Funds	376	514
TOTAL	2,497	2,356
<u>APPLICATION OF FUNDS</u>		
Fixed Assets (Net)	1,294	1,241
Intangible Assets	225	173
Investments - Liquid Funds	443	383
Investments - Others	49	47
Inventories	425	372
Sundry debtors	486	446
Cash and bank balances	303	140
Loans and advances	220	134
Total Current Assets	1,434	1,092
Less: Current liabilities	947	580
Net Current assets	487	512
TOTAL	2,497	2,356

**BIOCON LIMITED (CONSOLIDATED) UNAUDITED
PROFIT & LOSS STATEMENT** (Rs Crores)

Particulars	Q3 FY 11	Q3 FY 10	Variance
<u>INCOME</u>			
Biopharmaceuticals - Biocon	431	307	40%
- Axicorp	218	259	-16%
Contract research	79	69	14%
Total Sales	728	635	15%
Other income	10	6	50%
Total Income / Revenues	738	642	15%
<u>EXPENDITURE</u>			
Material & Power Costs	384	371	4%
Staff costs	76	60	27%
Research & Development	55	17	220%
Other Expenses	45	61	-26%
Manufacturing, staff & other expenses	560	508	10%
PBDIT /EBITDA	178	133	34%
Interest and finance charges	7	3	143%
PBDT	171	130	31%
Depreciation	41	36	13%
PBT	131	94	39%
Taxes	29	11	160%
Profit before minority interest	102	83	22%
Add/(less): Minority interest	(1)	(2)	
NET PROFIT (PAT)	101	81	24%
EPS Rs	5.2	4.2	

Note: The figures are rounded off to nearest crores, percentages are based on absolute numbers

Biopharmaceuticals - Biocon includes licensing income of Rs 77 crores in Q3 FY 2011 vs. Rs 18 crores in Q3 FY 2010

**BIOCON LIMITED (CONSOLIDATED) UNAUDITED
PROFIT & LOSS STATEMENT** (Rs. Crores)

Particulars	YTD FY 11	YTD FY 10	Variance
<u>INCOME</u>			
Biopharmaceuticals - Biocon	1,102	845	30%
- Axicorp	738	659	12%
Contract research	229	207	11%
Total Sales	2,069	1,711	21%
Other income	28	28	
Total Income / Revenues	2,097	1,739	21%
<u>EXPENDITURE</u>			
Material & Power Costs	1,191	1,008	18%
Staff costs	215	168	28%
Research & Development	96	59	64%
Other Expenses	125	135	-8%
Manufacturing, staff & other expenses	1,626	1,370	19%
PBDIT /EBITDA	471	369	28%
Interest and finance charges	20	14	47%
PBDT	451	356	27%
Depreciation	117	104	13%
PBT	334	252	32%
Taxes	61	34	78%
Profit before minority interest	273	218	25%
Add/(less): Minority interest	(6)	(5)	18%
NET PROFIT (PAT)	267	213	25%
EPS Rs.	13.6	10.9	

Note: The figures are rounded off to nearest crores, percentages are based on absolute numbers

Biopharmaceuticals - Biocon includes licensing income of Rs 122 crores in Ytd FY 2011 vs. Rs 30 crores in Ytd FY 2010.